Skip to main content
. Author manuscript; available in PMC: 2015 Nov 7.
Published in final edited form as: Vaccine. 2012 Nov 20;30(0 5):F123–F138. doi: 10.1016/j.vaccine.2012.04.108

Table 9.

Efficacy of Gardasil® against HPV6/11/16/18-related endpoints in mid-adult women

Endpoint ATP
% Efficacy (95% CI)		 ITT
% Efficacy (95% CI)
Persistent infection, CIN or EGL 88.7 (78.1–94.8) 47.2 (33.5–58.2)
Persistent infection 89.6 (79.3–95.4) 49.0 (35.5–59.9)
CIN – any grade 94.1 (62.5–99.9) 47.5 (16.3–67.7)
CIN2/3 83.3 (37.6–99.6) 22.4 (42.5–58.3)
EGL 100 (30.8–100) 8.5 (126.6–63.4)

ATP: According to Protocol; CI: Confidence interval; CIN: Cervical intraepithelial neoplasia; EGL: External genital lesion; ITT: Intention-to-treat. Data from reference [46].